跳至主要内容
临床试验/CTRI/2022/03/041060
CTRI/2022/03/041060尚未招募1 期

SAFETY, TOLERABILITY AND EFFICACY OF 2â??-O-METHYL-PHOSPHOROTHIOATE ANTI SENSE OLIGORIBONUCLEOTIDES FOR THE TREATMENT OF CONFIRMED DUCHENNE MUSCULAR DYSTROPHY OF INDIAN PEDIATRIC PATIENTS: PHASE 1 -OPEN LABELED STUDY

Muscular Dystrophy Patients Welfare Society0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Written informed to be sign
  • 2 Should of out frame deletion
  • 3 Not ventilator dependent
  • 4 Life expectancy of at least 6 months
  • 6 Within 6 months no treatment with investigational medicine

排除标准

  • 1 Max presence of dystrophin 5 percentage
  • 2 If FVC less than 60 percentage
  • 3 If Creatinine clearance less than 70 percentage
  • 4 If EF less than 30 percentage
  • 5 If history of respiratory insufficiency
  • 6 Severe Cognitive dysfunction
  • 7 If any immune deficiency
  • 8 If any known bleeding disorder
  • 9 Receipt of Pharmacologic treatment apart from corticosteroids
  • 10 Surgery within 6 months
  • 11 Acute illness within 4 weeks
  • 12 If have psychiatric disorder
  • 13 Experimental treatment within 4 weeks

研究者

发起方
Muscular Dystrophy Patients Welfare Society

相似试验